FMR1 and fragile X syndrome: To date, several studies have demonstrated that pharmacological approaches have the potential to ameliorate FXS pathology in Fmr1 knockout mice, a commonly used FXS experimental model (Gantois et al., 2017; Dy et al., 2018).